Evaluating the predictive and prognostic potential of novel immunologic tumor-based biomarkers in early stage breast cancer

The purpose of this study is to evaluate whether next-generation immune-based assays, such as TcR sequencing or RNA transcriptional profiling, can predict clinical response in early stage breast cancer.


Tumors will be retrospectively collected from subjects who meet the following criteria
• Diagnosis of early stage breast cancer;
• Treated at Providence Health and Services with either neoadjuvant systemic therapy or adjuvant systemic therapy
• At least 25um of tumor-bearing FFPE-preserved pre-treatment biopsy tissue must be available for analysis.
• For subjects receiving adjuvant therapy, clinical records of long-term follow-up (at least 1 year) must be available to provide adequate clinical correlation. For subjects receiving neoadjuvant therapy, 1 year of clinical follow-up and/or documentation of pathologic response to systemic therapy is required.
David Page, M.D.
Earle A Chiles Research Institute (EACRI)
Nikki Moxon
  • Oncology and Hematology Care Eastside